학술논문
Subcutaneous Interferon Beta-1a 22/44 mg Demonstrates Comparable Effectiveness Versus Teriflunomide in Newly Treated Patients with Multiple Sclerosis. a Study in a French Nationwide Cohort of Multiple Sclerosis: Observatoire Francais De La Sclérose En Pla
Document Type
Abstract
Author
Source
In Multiple Sclerosis and Related Disorders January 2020 37
Subject
Language
ISSN
2211-0348